Analysis of Factors Influencing the Interchangeability of Antiepileptic Drugs
- Authors: Alyautdin R.N.1, Romanov B.K.1, Pasternak E.Y.1, Bunyatyan N.D.1, Merkulov V.A.1
- 
							Affiliations: 
							- Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation
 
- Issue: Vol 50, No 3 (2016)
- Pages: 181-184
- Section: Drugs
- URL: https://ogarev-online.ru/0091-150X/article/view/244339
- DOI: https://doi.org/10.1007/s11094-016-1418-x
- ID: 244339
Cite item
Abstract
The presence of several generics on the pharmaceutical market makes it possible to create a competitive environment and helps to reduce the costs of drug therapy. RF Government Decree No. 1154 of October 28, 2015, “On the procedure for determining the interchangeability of drugs for medical use” determines largely the fate of generics in Russia. Quality assurance of generics and the creation of a competitive environment for the procurement of pharmaceutical products by regional public health institutions in order to reduce costs were the primary drivers of this decree. However, results from substitution of antiepileptic drugs indicate a number of problems in this field. The present review is devoted to an analysis of the interchangeability problems of antiepileptic drugs.
About the authors
R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation
							Author for correspondence.
							Email: alyautdin@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 127051						
B. K. Romanov
Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation
														Email: alyautdin@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 127051						
E. Yu. Pasternak
Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation
														Email: alyautdin@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 127051						
N. D. Bunyatyan
Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation
														Email: alyautdin@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 127051						
V. A. Merkulov
Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Public Health of the Russian Federation
														Email: alyautdin@mail.ru
				                					                																			                												                	Russian Federation, 							Moscow, 127051						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					